Valeria Calsolaro
Alzheimer's Research UK
United Kingdom
Evaluation of microglial activation in Alzheimers disease and mild cognitive impairment subjects using a novel TSPO marker, GE180
Alzheimer's Research UK
59,511
01/06/14
2.0
Alzheimer's disease & other dementias
Imaging Biomarkers | PET Non-Amyloid Imaging
Mild cognitive impairment (MCI) is a transitional stage between normal awareness and Alzheimers disease (AD). Brain inflammation has been proposed to be a link between the build-up of amyloid (an abnormal protein in the brains of patients with AD), damage to nerve cells and formation of tangles (clumps of proteins). With PET scanning we have demonstrated that AD subjects have significantly increased amyloid build-up and brain inflammation (demonstrated by increased activity of microglial cells). [18F]GE180 is a PET imaging agent that has been developed for the assessment of brain inflammation. The action of [18F]GE180 is based on its ability to bind to the translocator protein (TSPO). TSPO levels in the normal central nervous system are very low, but increase dramatically in microglial cells in response to brain damage and inflammation. Here we would like to evaluate [18F]GE180 in ten AD subjects, ten MCI subjects and ten healthy volunteers. This will be compared with the levels of amyloid imaged with [18F]flutemetamol, allowing us to better define the role of inflammation in AD and MCI subjects and to determine whether [18F]GE180 gives a suitable signal to assess the role of inflammation in disease progression and to evaluate the effect of anti-microglial agents.